JP2025032113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025032113A5 JP2025032113A5 JP2024197045A JP2024197045A JP2025032113A5 JP 2025032113 A5 JP2025032113 A5 JP 2025032113A5 JP 2024197045 A JP2024197045 A JP 2024197045A JP 2024197045 A JP2024197045 A JP 2024197045A JP 2025032113 A5 JP2025032113 A5 JP 2025032113A5
- Authority
- JP
- Japan
- Prior art keywords
- linker segment
- heterodimer
- monomeric
- subunit
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810376920.1 | 2018-04-25 | ||
| CN201810376920.1A CN110396133B (zh) | 2018-04-25 | 2018-04-25 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| JP2020559408A JP2021521822A (ja) | 2018-04-25 | 2019-04-24 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
| PCT/US2019/028933 WO2019209965A2 (en) | 2018-04-25 | 2019-04-24 | Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559408A Division JP2021521822A (ja) | 2018-04-25 | 2019-04-24 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025032113A JP2025032113A (ja) | 2025-03-11 |
| JP2025032113A5 true JP2025032113A5 (https=) | 2025-07-10 |
Family
ID=68294664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559408A Pending JP2021521822A (ja) | 2018-04-25 | 2019-04-24 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
| JP2024197045A Pending JP2025032113A (ja) | 2018-04-25 | 2024-11-11 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559408A Pending JP2021521822A (ja) | 2018-04-25 | 2019-04-24 | インターロイキン１２融合タンパク質および組成物、ならびにその治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12473337B2 (https=) |
| JP (2) | JP2021521822A (https=) |
| KR (1) | KR20210024446A (https=) |
| CN (2) | CN110396133B (https=) |
| AU (1) | AU2019261411B2 (https=) |
| BR (1) | BR112020021791A2 (https=) |
| CA (1) | CA3097995A1 (https=) |
| EA (1) | EA202092459A1 (https=) |
| WO (1) | WO2019209965A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210017247A1 (en) | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| MX2022000991A (es) * | 2019-07-25 | 2022-05-24 | Univ Chicago | Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa. |
| WO2021142471A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021248919A1 (en) * | 2020-04-01 | 2022-10-13 | Xilio Development, Inc. | Masked IL-12 cytokines and their cleavage products |
| WO2022115865A2 (en) * | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| WO2022129313A1 (en) * | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | Precursor proteins and kit for targeted therapy |
| IL306074A (en) * | 2021-03-24 | 2023-11-01 | Alkermes Inc | UPAR antibodies and fusion proteins with them |
| CN117396229A (zh) * | 2021-04-21 | 2024-01-12 | Cue生物制药股份有限公司 | Mhc ii类t细胞调节多肽及其使用方法 |
| TW202321282A (zh) * | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| JP2024539139A (ja) | 2021-10-20 | 2024-10-28 | シンセカイン インコーポレイテッド | ヘテロ二量体ｆｃサイトカインおよびその使用 |
| EP4649088A1 (en) * | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CN121263432A (zh) | 2023-04-12 | 2026-01-02 | 上海康抗生物技术有限公司 | 包含掩蔽型白介素12的多功能分子及使用方法 |
| WO2025119304A1 (en) * | 2023-12-07 | 2025-06-12 | Wuxi Biologics (Shanghai) Co., Ltd. | Heterodimeric proteins against il-12 receptor |
| WO2025256578A1 (zh) * | 2024-06-12 | 2025-12-18 | 龙启生物制药(杭州)有限公司 | Treg细胞靶向IL12融合蛋白及其制备、治疗方法 |
| WO2026020161A1 (en) * | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ATE194384T1 (de) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | Tnf-bindende proteine |
| DE69334070T2 (de) | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
| AU1407997A (en) | 1995-12-01 | 1997-06-19 | Beth Israel Hospital | Il-12 p40 subunit fusion polypeptides and uses thereof |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998028427A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| EP1489100B1 (en) | 1997-12-08 | 2016-06-15 | Merck Patent GmbH | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| EP1418184A1 (en) * | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| JP4718274B2 (ja) | 2005-08-25 | 2011-07-06 | 東京エレクトロン株式会社 | 半導体製造装置，半導体製造装置の流量補正方法，プログラム |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| PT3107573T (pt) * | 2014-02-19 | 2019-01-10 | Merck Patent Gmbh | Imunoterapia com il-12 visada ao cancro |
| CN105543279A (zh) * | 2014-10-30 | 2016-05-04 | 常州卡斯比生物科技有限公司 | 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂 |
| CN104628870A (zh) * | 2015-02-04 | 2015-05-20 | 中国药科大学 | 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白 |
| CN105218682B (zh) * | 2015-10-26 | 2019-05-07 | 杨晶 | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 |
| EP3184548A1 (en) * | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| WO2018030806A1 (ko) * | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| MX386014B (es) * | 2016-08-10 | 2025-03-18 | Univ Ajou Ind Academic Coop Found | Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma. |
-
2018
- 2018-04-25 CN CN201810376920.1A patent/CN110396133B/zh active Active
-
2019
- 2019-04-24 KR KR1020207033158A patent/KR20210024446A/ko not_active Ceased
- 2019-04-24 CN CN201980042842.4A patent/CN112638938A/zh active Pending
- 2019-04-24 BR BR112020021791-3A patent/BR112020021791A2/pt unknown
- 2019-04-24 AU AU2019261411A patent/AU2019261411B2/en active Active
- 2019-04-24 EA EA202092459A patent/EA202092459A1/ru unknown
- 2019-04-24 JP JP2020559408A patent/JP2021521822A/ja active Pending
- 2019-04-24 US US17/049,021 patent/US12473337B2/en active Active
- 2019-04-24 CA CA3097995A patent/CA3097995A1/en active Pending
- 2019-04-24 WO PCT/US2019/028933 patent/WO2019209965A2/en not_active Ceased
-
2024
- 2024-11-11 JP JP2024197045A patent/JP2025032113A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025032113A5 (https=) | ||
| JP2021521822A5 (https=) | ||
| JPWO2019213517A5 (https=) | ||
| CN103349781B (zh) | 具有改善的药物动力学特性的修饰嵌合多肽 | |
| JP2021530243A5 (https=) | ||
| JP2020508691A5 (https=) | ||
| JPWO2019209965A5 (https=) | ||
| CN112105634A (zh) | 新型白介素2及其用途 | |
| CN113968913A (zh) | 抗cd70嵌合抗原受体 | |
| HRP20030192A2 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug | |
| JPH07501698A (ja) | 二価特異性ヘテロ二量体 | |
| US20030187224A1 (en) | Chimeric OPG polypeptides | |
| JPH06239896A (ja) | 混成タンパク質 | |
| EA002688B1 (ru) | Способы инактивации клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, используемые для получения этих агентов | |
| EA011992B1 (ru) | Гибридный белок антитела l19 к фибронектину ed-b и интерлейкина 12 | |
| KR20050007359A (ko) | 종양 치료를 위한 면역접합체 | |
| JPWO2020023702A5 (https=) | ||
| CA2484425A1 (en) | Fusions of cytokines and tumor targeting proteins | |
| AU2017357649A1 (en) | Chimeric antigen receptor | |
| RU2020128838A (ru) | Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16) | |
| WO1991019515A1 (en) | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity | |
| JP2021502829A (ja) | Ｉｌ−３６を分泌する免疫応答性細胞およびその使用 | |
| WO1992008801A1 (en) | Bridging antibody fusion constructs | |
| WO2021032116A1 (zh) | 一种免疫细胞因子及其制备与用途 | |
| EP0868920A2 (en) | Hybrid protein for treatment of bladder cancer cells |